Pharmaust jumps on promising results from motor neurone disease drug trial

Neurizon Therapeutics

02/12/2022 04:47

** Shares of Pharmaust Ltd  PAA.AX  rise as much as 10.9% to
A$0.071
    ** Stock set for best day since Nov. 23, if gains hold
    ** Biotechnology co announces the completion of enrollment
of first cohort of patients for its phase 1/2 clinical trial of
its drug candidate monepantel (MPL) used for treatment of motor
neurone disease/amyotrophic lateral sclerosis  urn:newsml:reuters.com:*:nASX6ShDtq
    ** Says at the first treatment level, MPL tablets have been
well tolerated by patients 
    ** Shares hits highest since Nov. 25 
    ** More than 622,110 shares trade hand compared to 30-day
average trading volume of 129,000 shares  
    ** PAA down 36% YTD as of last close 
 (Reporting by John Biju in Bengaluru)
 ((John.Biju@thomsonreuters.com;))